EKF Diagnostics EKDHF Stock
EKF Diagnostics Price Chart
EKF Diagnostics EKDHF Financial and Trading Overview
| EKF Diagnostics stock price | 0.35 USD |
| Previous Close | 0.35 USD |
| Open | 0.39 USD |
| Bid | 0.32 USD x 250000 |
| Ask | 0.4 USD x 250000 |
| Day's Range | 0.39 - 0.39 USD |
| 52 Week Range | 0.29 - 0.42 USD |
| Volume | 20K USD |
| Avg. Volume | 1.27K USD |
| Market Cap | 167.9M USD |
| Beta (5Y Monthly) | 0.526 |
| PE Ratio (TTM) | 39 |
| EPS (TTM) | 0.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | November 2, 2023 |
| 1y Target Est | N/A |
EKDHF Valuation Measures
| Enterprise Value | 139.42M USD |
| Trailing P/E | 39 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.2560742 |
| Price/Book (mrq) | 1.8261502 |
| Enterprise Value/Revenue | 2.704 |
| Enterprise Value/EBITDA | 13.722 |
Trading Information
EKF Diagnostics Stock Price History
| Beta (5Y Monthly) | 0.526 |
| 52-Week Change | 9.91% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 0.42 USD |
| 52 Week Low | 0.29 USD |
| 50-Day Moving Average | 0.33 USD |
| 200-Day Moving Average | 0.36 USD |
EKDHF Share Statistics
| Avg. Volume (3 month) | 1.27K USD |
| Avg. Daily Volume (10-Days) | 2K USD |
| Shares Outstanding | 430.5M |
| Float | 351.18M |
| Short Ratio | N/A |
| % Held by Insiders | 1.17% |
| % Held by Institutions | 74.86% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 4.11% |
| Operating Margin (ttm) | 12.88% |
| Gross Margin | 51.35% |
| EBITDA Margin | 19.70% |
Management Effectiveness
| Return on Assets (ttm) | 5.35% |
| Return on Equity (ttm) | 3.52% |
Income Statement
| Revenue (ttm) | 51.56M USD |
| Revenue Per Share (ttm) | 0.12 USD |
| Quarterly Revenue Growth (yoy) | 5.40% |
| Gross Profit (ttm) | 26.48M USD |
| EBITDA | 10.16M USD |
| Net Income Avi to Common (ttm) | 2.12M USD |
| Diluted EPS (ttm) | 0.01 |
| Quarterly Earnings Growth (yoy) | -95.70% |
Balance Sheet
| Total Cash (mrq) | 13.69M USD |
| Total Cash Per Share (mrq) | 0.03 USD |
| Total Debt (mrq) | 1.39M USD |
| Total Debt/Equity (mrq) | 1.97 USD |
| Current Ratio (mrq) | 4.161 |
| Book Value Per Share (mrq) | 0.21356402 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 9.71M USD |
| Levered Free Cash Flow (ttm) | 6.67M USD |
Profile of EKF Diagnostics
| Country | United States |
| State | N/A |
| City | Cardiff |
| Address | Avon House |
| ZIP | CF64 2EZ |
| Phone | 44 29 2071 0570 |
| Website | https://www.ekfdiagnostics.com |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | 301 |
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test HbA1c, fully automated hemoglobin A1c analyzer for the monitoring and management of diabetes; and STAT-Site W Beta-Hydroxybutyrate analyzer. In addition, the company offers Creamatocrit Plus, a breast milk analyzer; QuPID and True20 pregnancy tests; Lactate Scout Vet, a handheld lactate analyzer for veterinary care; Hemo Vet, a point-of-care hemoglobin and hematocrit analyzer; Lactate Scout Sport, a lactate analyzer for sports performance; Biosen series for sports; and EKF Link, a data management solution that integrates point-of-care analyzers. Further, it offers Beta-Hydroxybutyrate LiquiColor for monitoring ketosis; RaPET, a range of immunoassay kits; QuStick Strep A for Strep A infection treatment; Hema-Screen Lab Pack for detection of colorectal cancer; PrimeStore MTM, a molecular transport medium that preserves and stabilizes DNA and RNA; Uri-Trak 120M urine analyzer; and clinical chemistry reagents, controls, and standards. Additionally, the company provides precision fermentation, custom bioprocessing, and contract manufacturing solutions; and diagnostic enzymes that include arylacylamidase, beta-hydroxybutyrate dehydrogenase, and salicylate hydroxylase. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
Q&A For EKF Diagnostics Stock
What is a current EKDHF stock price?
EKF Diagnostics EKDHF stock price today per share is 0.35 USD.
How to purchase EKF Diagnostics stock?
You can buy EKDHF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for EKF Diagnostics?
The stock symbol or ticker of EKF Diagnostics is EKDHF.
Which industry does the EKF Diagnostics company belong to?
The EKF Diagnostics industry is Medical Devices.
How many shares does EKF Diagnostics have in circulation?
The max supply of EKF Diagnostics shares is 430.5M.
What is EKF Diagnostics Price to Earnings Ratio (PE Ratio)?
EKF Diagnostics PE Ratio is 34.69000000 now.
What was EKF Diagnostics earnings per share over the trailing 12 months (TTM)?
EKF Diagnostics EPS is 0.01 USD over the trailing 12 months.
Which sector does the EKF Diagnostics company belong to?
The EKF Diagnostics sector is Healthcare.